Table 3.
Clinical baseline characteristics by treatment groups
| Study | Ceftaroline group | Control group | Ceftaroline group | Control group | Ceftaroline group | Control group | Ceftaroline group | Control group | Ceftaroline group | Control group |
|---|---|---|---|---|---|---|---|---|---|---|
| PSI risk class III, n (%) | PSI risk class IV, n (%) | Severe CAPa, n (%) | Multilobar infiltrate, n (%) | Pleural effusion, n (%) | ||||||
| Jandourek et al.., 2014 [9] | 5 (21.7) | 5 (22.7) | 18 (78.3) | 15 (68.2) | – | – | 5 (21.7) | 5 (22.7) | 5 (21.7) | 5 (22.7) |
| File et al........, 2011 [10] | 190 (65.3) | 182 (60.7) | 101 (34.7) | 118 (39.3) | 82 (28.2) | 89 (29.7) | – | – | – | – |
| Low et al...., 2011 [11] | 170 (58.8) | 171 (62.6) | 119 (41.2) | 102 (37.4) | 99 (34.3) | 80 (29.3) | – | – | – | – |
| Shorr et al.........., 2013 [12] | 34 (49.3) | 37 (52.9) | 35 (50.7) | 33 (47.1) | 22 (31.9) | 32 (45.7) | 18 (26.1) | 21 (30.0) | 15 (21.7) | 13 (18.6) |
| File et al, 2010 [13] | 360 (62.1) | 353 (61.6) | 220 (37.9) | 220 (38.4) | – | – | – | – | – | – |
| Zhong et al.., 2015 [14] | 255 (67.0) | 265(69.4) | 126 (33.1) | 117 (30.6) | – | – | – | – | – | – |
| Arshad et al, 2016 [15] | – | – | – | – | – | – | – | – | – | – |
| Eckburg et al, 2012 [22] | 84 (54.5) | 82 (52.9) | 61 (39.6) | 61 (39.4) | – | – | – | – | – | – |
| Structural lung diseaseb, n (%) | Prior pneumonia, n (%) | Asthma, n (%) | Prior antimicrobial therapy, n (%) | Bacteremia, n (%) | ||||||
| Jandourek et al, 2014 [9] | – | – | – | – | – | – | – | – | 23 (100.0) | 22 (100.0) |
| File et al, 2011 [10] | 64 (22.0) | 60 (20.0) | 61 (21.0) | 51 (17.0) | 25 (8.6) | 25 (8.3) | 137 (47.1) | 143 (47.7) | 8 (2.7) | 9 (3.0) |
| Low et al, 2011 [11] | 96 (33.2) | 87 (31.9) | 62 (21.5) | 41 (15.0) | 24 (8.3) | 13 (4.8) | 100 (34.6) | 117 (42.9) | 15 (5.2) | 11 (4.0) |
| Shorr et al, 2013 [12] | – | – | – | – | – | – | 26 (37.7) | 32 (45.7) | 19 (27.5) | 13 (18.6) |
| File et al, 2010 [13] | 160 (27.6) | 147 (25.7) | 123 (21.2) | 92 (16.1) | 49 (8.4) | 38 (6.6) | – | – | 23 (4.0) | 20 (3.5) |
| Zhong et al, 2015 [14] | 120 (31.5)c | 121 (31.7)c | – | – | 21 (5.5) | 22 (5.8) | 80 (21.0) | 85 (22.3) | 3 (0.8) | 5 (1.3) |
| Arshad et al, 2016 [15] | 8 (20.0) | 31 (28.4) | – | – | – | – | 4 (11.8) | 24 (23.3) | – | – |
| Eckburg et al, 2012 [22] | 43 (27.9) | 41 (26.5) | – | – | – | – | 57 (37.0) | 68 (43.9) | 23 (14.9) | 21 (13.5) |
| Diabetes mellitus, n (%) | ||||||||||
| Jandourek et al, 2014 | – | – | ||||||||
| File et al, 2011 | – | – | ||||||||
| Low et al, 2011 | – | – | ||||||||
| Shorr et al, 2013 | – | – | ||||||||
| File et al, 2010 | – | – | ||||||||
| Zhong et al, 2015 | 62 (16.3) | 62 (16.3) | ||||||||
| Arshad et al., 2016 | 10 (25.0) | 20 (18.4) | ||||||||
| Eckburg et al..., 2012 | – | – | ||||||||
aModified ATS severe CAP criteria include the presence of three or more of the following at baseline: respiratory rate ≥ 30 breaths/min; O2,90% or PaO2,60 mmHg; multilobar infiltrates; confusion/disorientation; blood urea nitrogen level ≥ 20 mg/dL; leucopenia (WBC count,4000 cells/mm3); thrombocytopenia (platelet count,100,000 cells/mm3); hypothermia (core temperature,368C); systolic blood pressure,90 mmHg; or diastolic blood pressure ≤ 60 mmHg. (Niederman MS, Mandell LA, Anzuetto A et al............ Guidelines for the management of adults with community-acquired pneumonia: diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001; 163: 1730–54)
bDefined as any chronic parenchymal or airway disease [e.g. chronic obstructive pulmonary disease (emphysema, chronic bronchitis), bronchiectasis, or interstitial fibrosis]
conly COPD and chronic bronchitis